MAGEA1 and triple-negative breast carcinoma: MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells and Atezolizumab for the Treatment of Metastatic Triple Negative Breast Cancer, Urothelial Cancer and NSCLC